Physician profile
Alexa E Gozali
NPI 1407309594
$2,031.66
in general payments reported to CMS, 2019-2025
21 companies · $284 in 2025
The $284 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $43.96 · 2021: $90.92 · 2022: $357 · 2023: $460 · 2024: $796 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,539.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $523.82 | 2022-2024 | |
| Strata Skin Sciences, INC. | $329.29 | 2024-2025 | Xtrac |
| Amgen INC. | $174.74 | 2020-2025 | Otezla, Otezla |
| Abbvie INC. | $172.53 | 2021-2025 | |
| Pfizer INC. | $159.02 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $129.41 | 2022 | |
| Novo Nordisk INC | $119.72 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $52.94 | 2024 | Dupixent |
| Galderma Laboratories, L.P. | $48.65 | 2024-2025 | Nemluvio, Aklief |
| Novartis Pharmaceuticals Corporation | $42.02 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $39.66 | 2024 | Sotyktu |
| Revance Therapeutics, INC. | $32.00 | 2025 | Daxxify |
| Verrica Pharmaceuticals INC. | $31.20 | 2024-2025 | Ycanth |
| Biofrontera INC. | $29.22 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Lilly USA, LLC | $28.14 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $22.64 | 2023 | Vtama |
| Sun Pharmaceutical Industries INC. | $22.27 | 2025 | |
| Ucb, INC. | $20.86 | 2024 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $19.79 | 2024 | Zoryve |
| Janssen Biotech, INC. | $16.93 | 2023 | Tremfya |
| Allergan, INC. | $16.81 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexa Gozali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.